P21

P21 is an experimental peptide candidate investigated for cognition and neurological function. Evidence in humans remains limited, and it has no FDA approval.

• Cognitive Function

  Effective

  Research examines potential improvements in recall, concentration and the processing of information.

• Neuroprotection

  Moderate

  Potential neuronal protection involves limiting inflammatory injury and damage caused by oxidative stress.

• Mood & Anxiety

  Moderate

  Some studies suggest reduced anxiety alongside greater stability of mood.

• Stimulants (Modafinil, Adderall)

  Caution

• MAOIs / SSRIs

  Monitor

• Racetams

  Caution

• NAD+

  Compatible

• BPC-157

  Compatible

Diluent: Use bacteriostatic water; avoid saline because it may cause precipitation.

1. Let your refrigerated P21 vial warm to room temperature for 15–20 minutes before preparation.
2. Disinfect the vial’s rubber closure with an alcohol wipe, then wait until it has dried completely.
3. Use a sterile syringe to measure the calculated amount of bacteriostatic water. Avoid saline because precipitation may occur.
4. Add the water slowly against the vial’s inner wall. Keep the stream away from the dry powder itself.
5. Rotate the vial gently to mix its contents. Do not shake forcefully, because this can damage the peptide.
6. Wait 2–3 minutes for the powder to dissolve completely. Check that the liquid is transparent and has no color.
7. Measure your calculated subcutaneous dose with an insulin syringe after dissolution.
8. Choose the abdomen, upper arm or thigh for injection. Alternate the injection location each time to help prevent lipodystrophy.
9. Refrigerate the mixed solution at 2–8°C, and discard any remainder after 28 days. Use these steps only for an appropriate research formulation; follow the specific product instructions for prescription presentations.

Week 1–2

Small changes in concentration and mood may emerge, with improvements in sleep sometimes appearing early.

Week 2–4

Anecdotal human reports mention clearer thinking, easier word retrieval and less mental fog during this period.

Week 4–8

Possible cognitive changes become more consistent, including working-memory improvements and better responses to stress.

Week 8+

Cognitive and neurological benefits may continue and can persist after a cycle ends. These expectations are not established outcomes for every person.

• Headaches, especially early in use
• Mild restlessness or anxiety
• Irritation of the nose with intranasal dosing
• Disturbed sleep when administration is too near bedtime
• Changes in mood or emotional stability · Rare

P21: not approved in the US.

• US

  Not approved

  FDA — No US approval. Research use does not constitute approval for treatment in humans.

  Rx required

  No

  Telehealth

  N/A

1. Ciliary neurotrophic factor (CNTF) and related peptides in neuroprotection (2013)

2. The effect of exogenous ciliary neurotrophic factor on cell cycle and neural differentiation markers of in vitro model cells: New insights for future therapeutic approaches. (2021)

   PMID 33890305DOI 10.1002/cbf.3628